For example, if haploinsufficiency of PPP2R3B, a subunit of PP2A, aids in the development of hematological malignancies, this could expand the applications for pharmacological activators of PP2A, which are being explored in preclinical AML models [111]. This evidence concerns the gene PPP2R3B and acute myeloid leukemia.